Cambridge Healthtech Institute’s 22nd Annual

Recombinant Protein Therapeutics

Fusion Proteins & Beyond

January 20-21, 2020

Part of the Protein Engineering & Development pipeline


Cambridge Healthtech Institute’s Recombinant Protein Therapeutics conference presents the latest developments in non-antibody therapeutics from international leaders. The conference focuses on the varying designs of fusion protein-based therapies and the latest data from R&D to post-approval, including case studies. By combining modular building blocks that can reach targets not accessible to antibodies, Fusion Protein Therapies possess advantages over antibody-based therapies; their customizable functionality translates into lower patient dosing, reduced production costs, and improved product homogeneity. This conference will demonstrate how these molecules are being engineered to form more efficacious therapeutics that offer specificity with enhanced stability and longer half-life.


Coverage will include, but is not limited to:                                        

  • Fc engineering
  • Conquering disease with Fusion Protein Therapies
  • Boosting PK
  • Molecule design
  • Linkers & conjugation
  • Enhancing activity
  • Improving manufacturability
  • Controlled drug release
  • Immunogenicity
  • Case studies
  • Stability
  • Antibody/Domain-based fusions
  • Prolonging half-life
  • Assays
  • Binding
  • Delivery
  • Cytotoxic effects
  • Bifunctional fusion proteins
  • Chimeric proteins
  • Receptor traps
  • Pre-clinical & clinical development


* The program is subject to change without notice, due to unforeseen reason.

2020 Conferences & Training Seminars